Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATACAND | ANI Pharmaceuticals | N-020838 RX | 1998-06-04 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATACAND HCT | ANI Pharmaceuticals | N-021093 RX | 2000-09-05 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
atacand | New Drug Application | 2020-06-19 |
atacand hct | New Drug Application | 2020-05-07 |
candesartan | ANDA | 2025-01-16 |
candesartan cilexetil | NDA authorized generic | 2024-10-14 |
candesartan cilexetil and hydrochlorothiazide | ANDA | 2024-11-11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 15 | 12 | 27 | 27 | 22 | 103 |
Essential hypertension | D000075222 | — | I10 | 2 | 7 | 10 | 2 | 5 | 26 |
Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 6 | 7 | 4 | 18 |
Healthy volunteers/patients | — | — | — | 11 | — | — | 1 | 2 | 14 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 4 | 4 | 3 | 13 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | 5 | 3 | 10 |
Covid-19 | D000086382 | — | U07.1 | — | 2 | 4 | 2 | 1 | 8 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | 4 | 1 | 7 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | 4 | 2 | 7 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 5 | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | — | 2 | 1 | — | 1 | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 1 | 3 |
Hypercholesterolemia | D006937 | — | — | — | — | 3 | — | — | 3 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | 3 | — | — | 3 |
Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | 1 | — | 1 | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 1 | 1 | — | — | 2 |
Fibrosis | D005355 | — | — | 1 | 1 | 1 | — | — | 2 |
Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | 2 | — | — | 2 |
Pathologic constriction | D003251 | — | — | — | — | 2 | — | — | 2 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Headache | D006261 | — | R51 | — | 1 | — | — | 2 | 3 |
Cognitive dysfunction | D060825 | — | G31.84 | — | 3 | — | — | — | 3 |
Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
Peripheral nervous system diseases | D010523 | — | G64 | — | 1 | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
Cardio-renal syndrome | D059347 | — | — | 1 | 1 | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | — | — | — | 1 |
Alcoholic liver diseases | D008108 | EFO_0008573 | K70 | 1 | 1 | — | — | — | 1 |
Hepatitis c | D006526 | — | B19.2 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
Hyperphosphatemia | D054559 | — | — | 1 | — | — | — | — | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 2 | 2 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Hypoglycemia | D007003 | — | E16.2 | — | — | — | — | 1 | 1 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
Drug common name | Candesartan cilexetil |
INN | — |
Description | Candesartan is a benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. It is a benzimidazolecarboxylic acid and a biphenylyltetrazole. It is a conjugate acid of a candesartan(2-). |
Classification | Small molecule |
Drug class | angiotensin II receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 |
PDB | — |
CAS-ID | 139481-59-7 |
RxCUI | 214354 |
ChEMBL ID | CHEMBL1014 |
ChEBI ID | 3348 |
PubChem CID | 2541 |
DrugBank | DB13919 |
UNII ID | — |